BIOMARIN PHARMACEUTICAL INC - Common Stock, par value $0.001 per share (BMRN)

Historical Holders from Q1 2014 to Q3 2025

Symbol
BMRN on Nasdaq
CUSIP
09061G101
Type / Class
Equity / Common Stock, par value $0.001 per share
Shares outstanding
194M
All holders as of September 30, 2025
Q3 2025
Total 13F shares, excl. options
179M
Holdings value
$9.71B
% of all portfolios
0.009%
Grand Portfolio weight change
0%
Number of holders
559
Number of buys
287
Number of sells
-266
Average Value change %
+0%
Average buys %
+0.002%
Average sells %
-0.002%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of BIOMARIN PHARMACEUTICAL INC - Common Stock, par value $0.001 per share (BMRN)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
BlackRock, Inc. 10.8% $1.23B 20.6M BlackRock, Inc. Mar 31, 2025
PRIMECAP MANAGEMENT CO/CA/ 8.24% $925M 15.8M PRIMECAP MANAGEMENT CO/CA/ Jun 30, 2025
Capital Research Global Investors 4.8% -28.6% $544M -$228M 9.15M -29.6% Capital Research Global Investors Mar 31, 2025
VIKING GLOBAL INVESTORS LP 4.3% -35% $451M -$215M 8.32M -32.3% VIKING GLOBAL INVESTORS LP Sep 30, 2025

Institutional Holders of BIOMARIN PHARMACEUTICAL INC - Common Stock, par value $0.001 per share (BMRN)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q3 179M $9.71B -$259M $54.16 559
2025 Q2 184M $10.1B +$85.9M $54.97 575
2025 Q1 181M $12.8B -$83.7M $70.69 575
2024 Q4 183M $12B +$367M $65.73 531
2024 Q3 177M $12.4B -$694M $70.29 545
2024 Q2 185M $15.2B +$201M $82.33 551
2024 Q1 183M $16B -$290M $87.34 549
2023 Q4 1.58M $152M +$8.47M $96.42 8
2023 Q3 177M $15.7B +$286M $88.48 498
2023 Q2 172M $14.9B -$352M $86.68 535
2023 Q1 176M $17.1B -$406M $97.24 534
2022 Q4 182M $18.8B +$42.4M $103.49 561
2022 Q3 181M $15.3B +$296M $84.77 521
2022 Q2 178M $14.7B +$129M $82.87 513
2022 Q1 175M $13.5B +$11.6M $77.10 528
2021 Q4 175M $15.4B +$129M $88.35 530
2021 Q3 175M $13.5B +$32.4M $77.29 493
2021 Q2 174M $14.5B -$129M $83.44 502
2021 Q1 175M $13.2B -$350M $75.51 508
2020 Q4 180M $15.7B +$287M $87.69 510
2020 Q3 179M $13.6B -$312M $76.08 476
2020 Q2 180M $22.2B +$737M $123.34 507
2020 Q1 174M $14.7B +$281M $84.50 476
2019 Q4 173M $14.6B +$51.1M $84.55 446
2019 Q3 173M $11.7B -$330M $67.40 418
2019 Q2 178M $15.2B +$318M $85.65 465
2019 Q1 178M $15.8B -$68.8M $88.83 468
2018 Q4 179M $15.2B -$188M $85.15 451
2018 Q3 181M $17.5B -$164M $96.97 442
2018 Q2 183M $17.2B +$327M $94.20 433
2018 Q1 179M $14.5B +$217M $81.07 414
2017 Q4 176M $15.7B +$262M $89.17 424
2017 Q3 175M $16.3B +$328M $93.07 402
2017 Q2 169M $15.3B +$171M $90.82 416
2017 Q1 169M $14.8B +$934M $87.78 407
2016 Q4 169M $14B +$54.3M $82.84 403
2016 Q3 168M $15.6B +$821M $92.52 417
2016 Q2 158M $12.3B -$246M $77.80 383
2016 Q1 161M $13.3B +$260M $82.48 373
2015 Q4 166M $16.9B +$174M $104.76 381
2015 Q3 159M $16.8B +$90.3M $105.32 385
2015 Q2 156M $21.3B +$182M $136.78 388
2015 Q1 157M $19.5B +$1.28B $124.62 373
2014 Q4 148M $13.3B +$113M $90.40 336
2014 Q3 148M $10.7B +$241M $72.16 312
2014 Q2 144M $8.96B -$420M $62.21 318
2014 Q1 147M $10B +$474M $68.21 307